PURPOSE: To determine whether parathyroid-hormone-related peptide (PTHRP) is an important pathogenetic mediator of hypercalcemia in patients with hematologic malignancies. PATIENTS AND METHODS: We conducted a cohort analytic study in 76 consecutive patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease, multiple myeloma, and Waldenstrom's macroglobulinemia, 14 of which were hypercalcemic. Thirty normal subjects served as a control group. RESULTS: Using the NH2 -terminal radioimmunoassay, PTHRP concentrations in heavy controls were undetectable (<7.5 pmol equivalents of PTHRP [fragment 1-34] per liter). The majority of hypercalcemic patients (8/14) had non-Hodgkin's lymphoma, and 62.5% of these (5/8) had significant elevations of circulating PTHRP concentrations (mean 70.5 +/- 38.5 pmol equivalents of PTHRP per liter) (P <0.01). In non-Hodgkin's lymphoma, 11 of 30 patients with advanced disease (stage IV) had elevated PTHRP concentrations, and of these, 8 of 11 had high-grade pathology. In contrast, only 3 or 21 patients with less advanced disease (stage I to III) had elevated PTHRP concentrations. In 4 NHL patients with less advance PTHRP concentrations sampled prior to cytotoxic chemotherapy, tumor response was associated with a decrease in PTHRP. Concomitant suppression of 1,25(OH)2D3 concentrations was observed in 66% of hypercalcemic patients with non-Hodgkin's lymphoma. CONCLUSIONS: These results suggest that PTHRP may be an important pathogenetic factor in the development of hypercalcemia in hematologic malignancies, notably in non-Hodgkin's lymphoma.
PURPOSE: To determine whether parathyroid-hormone-related peptide (PTHRP) is an important pathogenetic mediator of hypercalcemia in patients with hematologic malignancies. PATIENTS AND METHODS: We conducted a cohort analytic study in 76 consecutive patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease, multiple myeloma, and Waldenstrom's macroglobulinemia, 14 of which were hypercalcemic. Thirty normal subjects served as a control group. RESULTS: Using the NH2 -terminal radioimmunoassay, PTHRP concentrations in heavy controls were undetectable (<7.5 pmol equivalents of PTHRP [fragment 1-34] per liter). The majority of hypercalcemic patients (8/14) had non-Hodgkin's lymphoma, and 62.5% of these (5/8) had significant elevations of circulating PTHRP concentrations (mean 70.5 +/- 38.5 pmol equivalents of PTHRP per liter) (P <0.01). In non-Hodgkin's lymphoma, 11 of 30 patients with advanced disease (stage IV) had elevated PTHRP concentrations, and of these, 8 of 11 had high-grade pathology. In contrast, only 3 or 21 patients with less advanced disease (stage I to III) had elevated PTHRP concentrations. In 4 NHLpatients with less advance PTHRP concentrations sampled prior to cytotoxic chemotherapy, tumor response was associated with a decrease in PTHRP. Concomitant suppression of 1,25(OH)2D3 concentrations was observed in 66% of hypercalcemic patients with non-Hodgkin's lymphoma. CONCLUSIONS: These results suggest that PTHRP may be an important pathogenetic factor in the development of hypercalcemia in hematologic malignancies, notably in non-Hodgkin's lymphoma.
Authors: Jiarong Li; Andrew C Karaplis; Dao C Huang; Peter M Siegel; Anne Camirand; Xian Fang Yang; William J Muller; Richard Kremer Journal: J Clin Invest Date: 2011-11-07 Impact factor: 14.808
Authors: Katie N Evans; Harris Taylor; Daniel Zehnder; Mark D Kilby; Judith N Bulmer; Farah Shah; John S Adams; Martin Hewison Journal: Am J Pathol Date: 2004-09 Impact factor: 4.307
Authors: Anne Camirand; Ibtihal Fadhil; Aimée-Lee Luco; Benoît Ochietti; Richard B Kremer Journal: Am J Cancer Res Date: 2013-11-01 Impact factor: 6.166
Authors: Jason R Pitarresi; Robert J Norgard; Anna M Chiarella; Kensuke Suzuki; Basil Bakir; Varun Sahu; Jinyang Li; Jun Zhao; Benoît Marchand; Maximilian D Wengyn; Antony Hsieh; Il-Kyu Kim; Amy Zhang; Karine Sellin; Vivian Lee; Shigetsugu Takano; Yoji Miyahara; Masayuki Ohtsuka; Anirban Maitra; Faiyaz Notta; Richard Kremer; Ben Z Stanger; Anil K Rustgi Journal: Cancer Discov Date: 2021-02-15 Impact factor: 38.272
Authors: Ana Abaroa-Salvatierra; Bilal Shaikh; Mrunalini Deshmukh; Richard Alweis; Arti Patel Journal: J Community Hosp Intern Med Perspect Date: 2016-04-25